Search

everythinglearnresearchcommunity

for

Search:↓

Identical p53 gene mutations in different cancers suggest the need for careful treatment.

A man developed temporary hair loss after taking a cancer drug, which might indicate a better treatment response.

Alopecia areata is an autoimmune disease where T cells attack hair follicles.

The document concludes that ERBB2 mutations are common in extramammary Paget disease and may respond to systemic treatments like cancer immunotherapy.

WNT10A helps esophageal cancer cells spread and keep renewing themselves.

Some Greek melanoma patients have gene mutations linked to increased cancer risk, a new color feature helps diagnose melanoma, the incidence of a skin condition in the Netherlands is rare, and a gene possibly affects male-pattern baldness.

Myeloid-derived suppressor cells help control autoimmune cells and promote hair regrowth in alopecia areata.

CD90 is abundantly present on stem-like cells in dog hair follicles.

ILC1-like cells can cause alopecia areata by affecting hair follicles.

Increased ornithine decarboxylase makes normally tumor-resistant mice more sensitive to tumors.

The humanized AA mouse model is better for testing new alopecia areata treatments.

The new aptamer TAGX-0003 shows promise as an effective treatment for hair loss disorder alopecia areata.

IL-15 promotes hair growth and protects hair follicles.

RAR-gamma 1 is important for normal skin maintenance and differentiation.

MCHR2 gene duplications may be linked to alopecia areata.

Overexpressing NSD3 in mice causes breast cancer-like tumors and gland abnormalities.

The growth of the Epstein-Barr virus in the patient's cells was linked to the worsening of her lymphoma.

AD198 is more effective than doxorubicin in stopping certain dog cancer cells.

The new antibody, TYHF-1, specifically targets certain hair-related structures.

Alopecia areata patients show unique protein activity patterns, suggesting imbalanced signaling pathways.

Melanogenesis-related proteins may trigger immune responses in alopecia areata patients.

The protein folliculin, involved in a rare disease, works with another protein to control how cells stick together and their organization, and changes in this interaction can lead to disease symptoms.

Tofacitinib helps improve skin conditions in people with Down syndrome, especially alopecia areata.

Skin-resident memory T cells may contribute to chronic alopecia areata and baricitinib could be a potential treatment.